Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Preprint |
| Published: |
2025
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2501.12453 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Hybrid clinical trials, that borrow real-world data (RWD), are gaining interest, especially for rare diseases. They assume RWD and randomized control arm be exchangeable, but violations can bias results, inflate type I error, or reduce power. A two-step hybrid design first tests exchangeability, reducing inappropriate borrowing but potentially inflating type I error (Yuan et al., 2019). We propose four methods to better control type I error. Approach 1 estimates the variance of test statistics, rejecting the null hypothesis based on large sample normal approximation. Approach 2 uses a numerical approach for exact critical value determination. Approach 3 splits type I error rates by equivalence test outcome. Approach 4 adjusts the critical value only when equivalence is established. Simulation studies using a hypothetical ALS scenario, evaluate type I error and power under various conditions, compared to the Bayesian power prior approach (Ibrahim et al., 2015). Our methods and the Bayesian power prior control type I error, whereas Yuan et al. (2019) increases it under exchangeability. If exchangeability doesn't hold, all methods fail to control type I error. Our methods show type I error inflation of 6%-8%, compared to 10% for Yuan et al. (2019) and 16% for the Bayesian power prior.